Nav: Home

New leukemia drug is more effective and easier to use

January 11, 2019

MAYWOOD, IL - A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL).

The drug, ibrutinib, attacks cancer cells without damaging normal cells, thus causing fewer side effects. The drug is taken as a pill once a day - much more convenient than the standard treatment requiring the patient to come in three times a month for infusions and an injection.

"Ibrutinib should become the new standard of care," said Loyola oncologist Scott Smith, MD, PhD, one of the senior authors of the study, which was published in The New England Journal of Medicine.

In 2016, the U.S. Food and Drug Administration approved ibrutinib (brand name, Imbruvica) for treatment of CLL.

Dr. Smith is a professor in the division of ematology/oncology, department of medicine of Loyola Medicine and Loyola University Chicago Stritch School of Medicine. He was executive officer of the Alliance for Clinical Trials in Oncology, which coordinated the study, and was responsible for the execution of the study.

CLL, a disease of the immune system, is the most common form of leukemia in adults. It affects mainly older adults, with the average age of diagnosis around 70. The risk is higher in men.

Until now, the standard treatment has been a combination of a chemotherapy drug (bendamustine) that kills cancer cells and an immunotherapy drug (rituximab) that suppresses the immune system.

The study enrolled 547 CLL patients (67 percent male) at 219 centers in the United States and Canada. All were older than 65, with a median age of 71. Researchers randomly assigned patients to receive one of three regimens: the standard treatment of bendamustine plus rituximab; ibrutinib alone; or ibrutinib plus rituximab. After two years, 87 percent of patients receiving ibrutinib alone were alive without any disease progression, compared with 74 percent of patients who received bendamustine plus rituximab. There was no significant difference between patients receiving ibrutinib alone and those receiving ibrutinib plus rituximab.

About 17 percent of patients who received ibrutinib alone experienced an irregular heartbeat called atrial fibrillation. But overall, the drug caused fewer side effects than the standard treatment, Dr. Smith said.

Additional studies of ibrutinib are underway in CLL patients younger than age 65, Dr. Smith said.
-end-
The study, published Dec. 27, 2018, is titled "Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL." First author is Jennifer Woyach, MD, of Ohio State University.

As an academic medical center, Loyola is able to offer hundreds of cancer clinical trials, giving patients access to many new cancer drugs and therapies that are not available at most hospitals. Therapies under study at Loyola include targeted therapy, immunotherapy and new forms of surgery, chemotherapy and radiation.

Loyola University Health System

Related Leukemia Articles:

Cocktail proves toxic to leukemia cells
Rice bioscientists find a way to predict the sensitivity of acute myeloid leukemia to mitochondria-damaging molecules and develop cocktails to fight the cancer.
The drug combination effective against bovine leukemia
Scientists have succeeded in reducing levels of the bovine leukemia virus (BLV) in cows with severe infections by combining an immune checkpoint inhibitor and an enzyme inhibitor.
Towards a safer treatment for leukemia
An international team of researchers at VIB-KU Leuven, Belgium, the UK Dementia Institute and the Children's Cancer Institute, Australia, have found a safer treatment for a specific type of leukemia.
Research paves way for new source for leukemia drug
Chemistry researchers have patented a method for making anti-leukemia compounds that until now have only been available via an Asian tree that produces them.
An atlas of an aggressive leukemia
A team of researchers led by Bradley Bernstein at the Ludwig Center at Harvard has used single-cell technologies and machine learning to create a detailed 'atlas of cell states' for acute myeloid leukemia (AML) that could help improve treatment of the aggressive cancer.
Finding second hits to knock out leukemia
Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks.
Understanding the emergence of leukemia
Acute T-cell lymphoblastic leukemia is a rare type of blood cancer that affects mostly children.
New treatment approach for leukemia
An international research team led by researchers from Vetmeduni Vienna have made an important discovery that could lead to a better understanding of lymphocytic leukemia.
More accurate leukemia diagnosis expected as researchers refine leukemia classification
Research led by St. Jude Children's Research Hospital means more than 90 percent of the most common cases of childhood cancer can now be classified by subtype, an advance likely to fuel precision medicine.
New leukemia drug is more effective and easier to use
A landmark study co-authored by a Loyola Medicine oncologist has found that a newer targeted drug is significantly more effective than standard therapy for treating elderly patients with chronic lymphocytic leukemia (CLL).
More Leukemia News and Leukemia Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#541 Wayfinding
These days when we want to know where we are or how to get where we want to go, most of us will pull out a smart phone with a built-in GPS and map app. Some of us old timers might still use an old school paper map from time to time. But we didn't always used to lean so heavily on maps and technology, and in some remote places of the world some people still navigate and wayfind their way without the aid of these tools... and in some cases do better without them. This week, host Rachelle Saunders...
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.